BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1099 related articles for article (PubMed ID: 22314188)

  • 1. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features.
    Chang DT; Pai RK; Rybicki LA; Dimaio MA; Limaye M; Jayachandran P; Koong AC; Kunz PA; Fisher GA; Ford JM; Welton M; Shelton A; Ma L; Arber DA; Pai RK
    Mod Pathol; 2012 Aug; 25(8):1128-39. PubMed ID: 22481281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma.
    Kakar S; Deng G; Smyrk TC; Cun L; Sahai V; Kim YS
    Mod Pathol; 2012 Jul; 25(7):1040-7. PubMed ID: 22522845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
    Ma C; Olevian D; Miller C; Herbst C; Jayachandran P; Kozak MM; Chang DT; Pai RK
    Mod Pathol; 2019 Jul; 32(8):1217-1231. PubMed ID: 30962505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
    Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
    BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
    Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
    Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
    Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
    Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features.
    Rosty C; Young JP; Walsh MD; Clendenning M; Walters RJ; Pearson S; Pavluk E; Nagler B; Pakenas D; Jass JR; Jenkins MA; Win AK; Southey MC; Parry S; Hopper JL; Giles GG; Williamson E; English DR; Buchanan DD
    Mod Pathol; 2013 Jun; 26(6):825-34. PubMed ID: 23348904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
    Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
    J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
    Yoon HH; Tougeron D; Shi Q; Alberts SR; Mahoney MR; Nelson GD; Nair SG; Thibodeau SN; Goldberg RM; Sargent DJ; Sinicrope FA;
    Clin Cancer Res; 2014 Jun; 20(11):3033-43. PubMed ID: 24687927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR
    JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.
    Lochhead P; Imamura Y; Morikawa T; Kuchiba A; Yamauchi M; Liao X; Qian ZR; Nishihara R; Wu K; Meyerhardt JA; Fuchs CS; Ogino S
    Eur J Cancer; 2012 Dec; 48(18):3405-13. PubMed ID: 22840368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated Quantitation of CD8-positive T Cells Predicts Prognosis in Colonic Adenocarcinoma With Mucinous, Signet Ring Cell, or Medullary Differentiation Independent of Mismatch Repair Protein Status.
    Hartman DJ; Frank M; Seigh L; Choudry H; Pingpank J; Holtzman M; Bartlett D; Bahary N; Pantanowitz L; Pai RK
    Am J Surg Pathol; 2020 Jul; 44(7):991-1001. PubMed ID: 32205483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer.
    Zlobec I; Bihl MP; Foerster A; Rufle A; Lugli A
    Histopathology; 2012 Nov; 61(5):777-87. PubMed ID: 22803799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.